Functional and ongological results of radical perineal prostatectomy for the management of clinically locally advanced prostate cancer. Single centre experience

Athanasios Ι. Archodakis, Stefanos Bolometes


Radical prostatectomy is considered to be the best choice for managing localized prostate cancer. There is increased evidence that a surgical approach has an important role to play as a method of treatment for locally advanced prostate cancer. According to the European Association of Urology (EAU), radical prostatectomy is an option for properly chosen patients with locally advanced prostate cancer. The aim of our study is to evaluate the oncological and functional results of radical perineal prostatectomy for the management of patients with clinically locally advanced prostate cancer.

Between 1993 and 2012, 627 patients underwent radical perineal prostatectomy for histologically confirmed prostate cancer. Eighty three out of 627 patients had clinically advanced disease. Perioperative morbidity, functional results and early oncological outcomes were examined and compared between the two groups.

There was no statistically significant difference between the two groups regarding operation time, intraoperative blood loss, length of hospital stay and duration of catheterization. The rate of complications was also similar, with the exception of two rectal injuries in the locally advanced group, though these were successfully repaired at the same time. In the locally advanced group, 17.3% of the clinically advanced patients had pathologically confined disease. Out of the patients  99.8% remained continent and 36.1% remained potent in the locally advanced group. In the organ confined group the rates were 100% and 62.5%, respectively. Between the two groups there was no significant difference regarding the cancer-specific survival rate.

Radical perineal prostatectomy is considered to be the best choice for treating locally advanced disease, provided patients are fully informed and that they consent to undergo this treatment.


Λειτουργικά και ογκολογικά αποτελέσματα της ριζικής περινεϊκής προστατεκτομής στην αντιμετώπιση του κλινικά προχωρημένου τοπικά καρκίνου προστάτη. Η Εμπειρία της ουρολογικής κλινικής του 401 ΓΣΝΑ

Εισαγωγή. Η ριζική προστατεκτομή θεωρείται ως η θεραπεία εκλογής στον εντοπισμένο καρκίνο του προστάτη. Τα τελευταία χρόνια πληθαίνουν οι βιβλιογραφικές αναφορές που υποστηρίζουν πως η χειρουργική αντιμετώπιση έχει θέση στην αντιμετώπιση της, τοπικά, προχωρημένης νόσου. Σύμφωνα με τις οδηγίες της Ευρωπαϊκής Ουρολο-
γικής Εταιρείας, η ριζική προστατεκτομή θεωρείται προαιρετική (optional) επιλογή σε καλά επιλεγμένους ασθενείς με, τοπικά, προχωρημένη νόσο. Σκοπός της παρούσας εργασίας είναι να αναδείξει τον ρόλο της περινεϊκής
προσπέλασης σε ασθενείς με, τοπικά, προχωρημένο καρκίνο προστάτη.

Υλικό και μέθοδος.  Μεταξύ 1993 και 2012,627 ασθενείς με καρκίνο προστάτη υποβλήθηκαν σε ριζική περινεϊκή προστατεκτομή. Απο τους ασθενείς αυτόυς 83 είχαν κλινικά, τοπικά, προχωρημένη νόσο. Συγκρίναμε τη μετεγχειρητική πορεία και τα πρώιμα ογκολογικά αποτελέσματα μεταξύ των δύο ομάδων.

Αποτελέσματα. Δεν παρατηρήθηκε διαφορά όσον αφορά στο μέσο χειρουργικό χρόνο, την απώλεια αίματος , την παραμονή στο νοσοκομείο και τη διάρκεια καθετηριασμού μεταξύ των δύο ομάδων. Δεν υπήρχε στατιστικά σηαντική διαφορά στις μετεγχειρητικές επιπλοκές και 2 διεγχειρητικές τρώσεις ορθού στην ομάδα της τοπικά προχωρημένης νόσου αποκαταστάθηκαν σε πρώτο χρόνο, επιτυχώς. Στην ομάδα της τοπικά προχωρημένης νόσου υπήρξε παθολογοανατομική υποσταδιοποίηση στο 17,3% των περιπτώσεων. Το 99,8% διατήρησαν την εγκράτεια τους και το 36,1 % την στυτική τους λειτουργία έναντι 100 και 62,5% στην ομάδα της εντοπισμένης νόσου. Δεν υπήρξε στατιστικά σημαντική διαφορά στην ειδική της νόσου επιβίωση μεταξύ των δύο ομάδων.


Radical perineal prostatectomy; locally advanced prostate cancer;

Full Text:



Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002 Jul;360(9327):103-6

Hodgson D, Warde P, Gospodarowicz M. The management of locally advanced prostate cancer. UrolOncol 1998;(4):3-12

Fallon B, Williams RD. Current options in the management of clinical stage C prostatic carci-noma. UrolClinNorthAm 1990 Nov;17(4):853-66

Boccon-Gibod L, Bertaccini A, Bono AV, et al. Management of locally advanced prostate cancer: a European Consensus. Int J ClinPract 2003 Apr;57(3):187-94

Yamada AH, Lieskovsky G, Petrovich Z, et al. Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stage TC, prostate cancer. Am J ClinOncol 1994 Aug;17(4):277-85

Hsu CY, Joniau S, Oyen R, et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. EurUrol 2007 Jan;51(1):121-8; discussion 128-9

Gerber GS, Thisted RA, Chodak GW, et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled

analysis. EurUrol 1997;32(4):385-90

Ward JF, Slezak JM, Blute ML, et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005 Apr;95(6): 751-6

Isorna Martinez de la Riva S, BelónLópez-Tomasety J, Marrero Dominguez R, et al. [Radical prostatectomy as monotherapy for locally advanced prostate cancer (T3a): 12 years follow-up]. ArchEspUrol 2004 Sep;57(7):679-92. [ArticleinSpanish]

Van den Ouden D, Hop WC, Schröder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998 Oct; 160(4):1392-7.

A. Heidenreich (chairman), P.J. Bastian, J. Bellmunt, M. Bolla, S. Joniau, M.D. Mason, V. Athanasios I. Archodakis, Stefanos Bolometes Matveev, N. Mottet, T.H. van der Kwast, T. Wiegel, F. Zattoni. EAU GuidelinesonProstateCancer 2012

Koutsilieris M, et al. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis. BJU Int. 2007 Jul;100 Suppl 2:60-2

S. Joniau, C. Y. Hsu, E. Lerut et al., “A pretreatment table for the prediction of final -histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer,” European Urology, vol. 51, no. 2, pp. 388—, 2007

S.G.Fletcher and D. Theodorescu, “Surgery or radiation:what is the optimal management for locally advanced prostate cancer?” The Cana-dianjournalo-furology, vol. 12, no. 1, supplement 1, pp. 58—, 2005

S. E. Lerner,M. L. Blute, and H. Zincke, “Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity,” Journal of Urology, vol. 154, no. 4, pp. 1447—, 1995

W. R. Morgan, E. J. Bergstralh, and H. Zincke, “Long-term evaluation of radical prosta-tectomy as treatment for clinical stage C (T3) prostate cancer,” Urology, vol. 41, no. 2, pp. 113—, 1993

J. F. Ward, J. M. Slezak, M. L. Blute, E. J. Bergstralh, and H. Zincke, “Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-Year outcome,” BJU International, vol. 95, no. 6, pp. 751—, 2005

K. A. Roehl, M. Han, C. G. Ramos, J. A. V. Antenor, and W. J. Catalona, “Cancer progression Functional and ongological results of radical perineal prostatectomy for the management of clinically locally advanced prostate cancer. Single centre experience and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results,” Journal of Urology, vol. 172, o. 3, pp. 910—, 2004

D. Van den Ouden, P. J. T. Davidson, W. Hop, and F. H. Schroder, “Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer,” Journal of Urology, vol. 151, no. 3, pp. 646—, 1994

H. Van Poppel, H. Goethuys, P. Callewaert, L. Vanuytsel, W. Van De Voorde, and L. Baert, “Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer,” European Urology, vol. 38, no. 4, pp. 372—, 2000.

G. S. Gerber, R. A. Thisted, G. W. Chodak et al., “Results of radical prostatectomy in men with locally advanced prostate cancer:multi-institutional pooled analysis,” European Urology, vol. 32, no. 4, pp. 385—, 1997

S. M. de la RivaIsorna, L.-T. J. Belon, D. R. Marrero, C. E. Alvarez, and B. P. Santamaria, “Radical prostatectomy asmonotherapy for locally advanced

prostate cancer (T3a): 12 years follow-up,” ArchivosEspa˜noles de Urolog´ıa, vol. 57, no. 7, pp. 679—, 2004

M. Bolla, H. Van Poppel, L. Collette et al., “Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911),”The Lancet, vol. 366, no.9485, pp. 572, 2005

Shelley MD, Kumar S, Wilt T, et al. A systematic review and meta-analysis of randomised trials of neoadjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer TreatRev 2009 Feb;35(1):9-17.25. Johnstone PA, Ward KC, Goodman M, et al. Radical prostatectomy for clinical T4 prostate cancer. Cancer 2006 Jun;106:2603-9

Zietman AL, Prince EA, Nakfoor BM, et al. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumour system. Int J RadiatOncolBiolPhys 1997 Jul;38(5):1067-70

Joon DL, Hasegawa M, Sikes C, et al. Supra-additive apoptotic response of R3327-G rat prostate tumours to androgen ablation and radiation. Int J RadiatOncolBiolPhys 1997 Jul;38(5):1071-7

C. Obek, S. Sadek, S. Lai, F. Civantos, D. Rubinowicz, and M. S. Soloway, “Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis andimpact on prognosis,” Urology, vol. 54, no. 4, pp. 682—, 1999

R. B.Watson, F. Civantos, and M. S. Solo-way, “Positive surgical margins with radical prosta-tectomy:detailed pathological analysis and prognosis,” Urology, vol. 48, no. 1, pp. 80—, 1996

D. I. Quinn, S. M. Henshall, A. M. Haynes et al., “Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: Implications for staging systems and predictive models,” Journal of Clinical Onco-logy, vol. 19, no. 16, pp. 3692—, 2001

S. S. Connolly, G. C. O’Toole, K. J. O’Malley et al., “Positive apical surgical margins after radical retropubic prostatectomy, truth or artefact?” ScandinavianJournalofUrologyandNephrology, vol. 38, no. 1, pp. 26—, 2004

S. R. Bott, A. A. Freeman, S. Stenning et al., “Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time,” BJU International, vol. 95, no. 1, pp. 34—, 2005